Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database.

cardiac arrest claims database drug discovery tool drug repositioning vasodilator

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2019
Historique:
received: 19 04 2019
accepted: 30 09 2019
entrez: 30 11 2019
pubmed: 30 11 2019
medline: 30 11 2019
Statut: epublish

Résumé

The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using "TargetMine," a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to ≥10 patients and the objective variable being the "survival discharge." Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to ≥10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients.

Identifiants

pubmed: 31780928
doi: 10.3389/fphar.2019.01257
pmc: PMC6857070
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1257

Informations de copyright

Copyright © 2019 Zamami, Niimura, Koyama, Shigemi, Izawa-Ishizawa, Morita, Ohshima, Harada, Imai, Hagiwara, Okada, Goda, Takechi, Chuma, Kondo, Tsuchiya, Hinotsu, Kano and Ishizawa.

Références

Nat Rev Drug Discov. 2004 Aug;3(8):673-83
pubmed: 15286734
Int J Med Sci. 2018 Nov 22;15(14):1686-1693
pubmed: 30588192
Intensive Care Med. 2000 Feb;26(2):255
pubmed: 10784324
Biomed Res Int. 2015;2015:314796
pubmed: 26421284
Clin Ther. 2016 Jun;38(6):1359-1375.e1
pubmed: 27101816
Eur J Pharmacol. 2014 Jul 5;734:42-9
pubmed: 24726850
Am J Cardiol. 1984 Jun 1;53(11):1725
pubmed: 6428213
Ann Thorac Surg. 1992 Oct;54(4):712-6
pubmed: 1417229
Resuscitation. 2010 Jan;81(1):129-30
pubmed: 19913980
J Med Invest. 2017;64(3.4):197-201
pubmed: 28954981
Circulation. 2013 Jan 1;127(1):e6-e245
pubmed: 23239837
Int J Clin Pharmacol Biopharm. 1979 Jan;17(1):1-11
pubmed: 33121
Resuscitation. 2010 Jul;81(7):919-20
pubmed: 20413206
Database (Oxford). 2016 Mar 17;2016:null
pubmed: 26989145
PLoS One. 2011 Mar 08;6(3):e17844
pubmed: 21408081
Nihon Kyobu Geka Gakkai Zasshi. 1990 Apr;38(4):630-40
pubmed: 2373897
J Am Coll Cardiol. 2002 Dec 18;40(12):2110-6
pubmed: 12505221

Auteurs

Yoshito Zamami (Y)

Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.

Takahiro Niimura (T)

Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

Toshihiro Koyama (T)

Department of Clinical Evaluation and Development of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Kita-ku, Japan.

Yuta Shigemi (Y)

Department of Emergency Pharmaceutical Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Yuki Izawa-Ishizawa (Y)

AWA Support Center, Tokushima University, Tokushima, Japan.

Mizuki Morita (M)

Biomedical Informatics, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Kita-ku, Japan.

Ayako Ohshima (A)

Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Kita-ku, Japan.

Keisaku Harada (K)

Department of Pharmacy, Kitakyushu City Yahata Hospital, Kitakyushu-shi, Japan.

Toru Imai (T)

Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.

Hiromi Hagiwara (H)

Department of Medical Innovation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Naoto Okada (N)

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.

Mitsuhiro Goda (M)

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.

Kenshi Takechi (K)

Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Masayuki Chuma (M)

Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Yutaka Kondo (Y)

Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan.

Koichiro Tsuchiya (K)

Department of Medical Pharmacology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.

Shiro Hinotsu (S)

Department of Biostatistics, Sapporo Medical University, Sapporo, Japan.

Mitsunobu R Kano (MR)

Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Kita-ku, Japan.

Keisuke Ishizawa (K)

Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.

Classifications MeSH